Interstitial pneumonitis caused by <i>Pneumocystis jirovecii</i> pneumonia (PCP) during bortezomib treatment

Wondergem, Mariëlle J.; Grünberg, Katrien; Wittgen, Bart P.H.; Sonneveld, Pieter

doi:10.1111/j.1365-2559.2009.03263.x

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, early evaluation did not encompass emerging subgroups of patients with haematological malignancy. The estimated risk of PJP in these groups, such as acute myeloid leukaemia, myelodysplasia, myeloma and lymphoma, are based on case reports and are incompletely defined.…”

Section: Determining Patient Risk and The Need For Pjp Prophylaxismentioning

confidence: 99%

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Cooley

Dendle

Wolf

et al. 2014

Internal Medicine Journal

192

179

View full text Add to dashboard Cite

Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprimsulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

show abstract

Section: Determining Patient Risk and The Need For Pjp Prophylaxismentioning

confidence: 99%

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Cooley

Dendle

Wolf

et al. 2014

Internal Medicine Journal

192

179

View full text Add to dashboard Cite

show abstract

“…Due to the depletion of T-cells and the subsequent impairment in viral antigen presentation, the use of PIs is associated with a higher risk for reactivation of viral infections, particularly VZV. PIs also impact on the net state of immunosuppression and, therefore, may increase the risk for opportunistic infections when used in combination with other immunosuppressive regimens [118].…”

Section: Proteasome Inhibitors: Bortezomib Carfilzomib and Ixazomibmentioning

confidence: 99%

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

Redelman-Sidi

Michielin

Cervera

et al. 2018

Clinical Microbiology and Infection

101

View full text Add to dashboard Cite

show abstract

“…Bortezomib is a reversible inhibitor of the 26S proteasome used for treatment of multiple myeloma, and extrapulmonary (intestinal) pneumocystosis has been associated with its use [48]. The basis for increased infection risk is also not clear.…”

Section: Signal Transduction Inhibitorsmentioning

confidence: 99%

Pneumocystis jirovecii pneumonia in non-HIV-infected patients

Reid

Chen

Worth

2011

Current Opinion in Infectious Diseases

114

View full text Add to dashboard Cite

HIV-negative populations at risk for PJP can be identified. Conventional PCR increases diagnostic sensitivity but may detect asymptomatic colonization. Quantitative PCR demonstrates potential for distinguishing colonization from infection, but clinical validation is required. Serum (1→3)-β-D-glucan may be elevated in PJP, although standardized cut-off values for clinical infection have not been determined. Further validation of serum markers and molecular diagnostic methods is necessary for early and accurate diagnosis in non-HIV populations.

show abstract

Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment

Cited by 9 publications

References 5 publications

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

Pneumocystis jirovecii pneumonia in non-HIV-infected patients

Contact Info

Product

Resources

About